Long-Term Clinical Outcome Based on Aspirin and Clopidogrel Responsiveness Status After Elective Percutaneous Coronary Intervention A 3T/2R (Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel) Trial Substudy

被引：108

作者：

Campo, Gianluca ^{[1
,2
]}

Fileti, Luca ^{[1
,2
]}

de Cesare, Nicoletta ^{[3
]}

Meliga, Emanuele ^{[4
]}

Furgieri, Alessandro ^{[5
]}

Russo, Filippo ^{[6
]}

Colangelo, Salvatore ^{[7
]}

Brugaletta, Salvatore ^{[8
]}

Ferrari, Roberto ^{[1
,2
]}

Valgimigli, Marco ^{[1
,2
]}

机构：

[1] Azienda Osped Univ S Anna, Cardiovasc Inst, Ferrara, Italy

[2] IRCCS, Fdn Salvatore Maugeri, Lumezzane, Italy

[3] Policlin S Marco, UO Cardiol, Bergamo, Italy

[4] ASO Mauriziano Umberto I, Intervent Cardiol Dept, Turin, Italy

[5] Villa Maria Cecilia Hosp, Dept Cardiol, Cotignola, Ravenna, Italy

[6] IRCCS, Policlin San Matteo, Lab Emodinam, Pavia, Italy

[7] Azienda Osped S Giovanni Bosco Hosp, Unit Cardiol, Turin, Italy

[8] St Paul Univ Hosp, Intervent Cardiol Unit, Barcelona, Spain

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2010年 / 56卷 / 18期

关键词：

aspirin; clopidogrel; glycoprotein IIb/IIIa inhibitor; percutaneous coronary intervention; poor response; 1-year outcome; OF-CARE ASSAY; PLATELET REACTIVITY; EVENTS; ACTIVATION; THERAPY;

D O I：

10.1016/j.jacc.2010.03.103

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives The purpose of this study was to investigate the long-term outcome after elective percutaneous coronary intervention in low-risk patients screened for aspirin and/or clopidogrel responsiveness in the 3T/2R (Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel) trial. Background The impact of aspirin and/or clopidogrel poor response on long-term outcome is debated. Methods Aspirin and clopidogrel response was measured with the VerifyNow system aspirin and P2Y12 assays. After percutaneous coronary intervention (PCI), death, stroke, and myocardial infarction were assessed up to 1 year. Results Overall, 1,277 patients were screened, and 826 (65%) were treated with PCI. In all, 124 patients were found to be aspirin poor responders, and there were 179 clopidogrel poor responders (totally, 278 poor responders). The 1-year end point was significantly higher in poor responders as compared to full responders (15.8% vs. 8.6%, p = 0.002), which is principally due to more myocardial infarction occurrence. At multivariable analysis, clopidogrel poor response emerged as an independent predictor (hazard ratio: 1.15, 95% confidence interval: 1.03 to 1.28). Receiver-operator characteristic analysis identifies <= 23 of percentage of platelet inhibition and >= 208 of P2Y(12) reactivity units as optimal cut offs to predict 1-year end point. Excluding periprocedural events, also peri-PCI myocardial infarction, which is strongly related to aspirin/clopidogrel poor response, was an independent predictor (hazard ratio: 1.25, 95% confidence interval: 1.14 to 1.37). Glycoprotein IIb/IIIa inhibitor administration reduces this risk in poor responders (21.2% vs. 34.7%, p = 0.02), but not in full responders (6.3% vs. 6.5%, p = 0.8). Conclusions Poor response to clopidogrel is an independent predictor of periprocedural myocardial infarction and worse 1-year outcome in low-risk patients undergoing PCI, whereas poor response to aspirin failed to predict a worse outcome. Contrary to what was observed in poor responders, glycoprotein IIb/IIa inhibitor therapy failed to provide a benefit in aspirin and/or clopidogrel full responders. (J Am Coll Cardiol 2010;56:1447-55) (C) 2010 by the American College of Cardiology Foundation

引用

页码：1447 / 1455

页数：9

共 25 条

[21] Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation [J].

Price, Matthew J. ;

Endemann, Sarah ;

Gollapudi, Raghava R. ;

Valencia, Rafael ;

Stinis, Curtiss T. ;

Levisay, Justin P. ;

Ernst, Alissa ;

Sawhney, Neil S. ;

Schatz, Richard A. ;

Teirstein, Paul S. .

EUROPEAN HEART JOURNAL, 2008, 29 (08) :992-1000

[22] Aspirin Resistance [J].

Tantry, Udaya S. ;

Mahla, Elisabeth ;

Gurbel, Paul A. .

PROGRESS IN CARDIOVASCULAR DISEASES, 2009, 52 (02) :141-152

[23] Universal definition of myocardial infarction [J].

Thygesen, Kristian ;

Alpert, Joseph S. ;

White, Harvey D. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (22) :2173-2195

[24] Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R).: Rationale for the study and protocol design [J].

Valgimigli, Marco ;

Campo, Gianluca ;

de Cesare, Nicoletta ;

Vranckx, Pascal ;

Hamon, Martial ;

Angiolillo, Dominick J. ;

Sabate, Manel ;

Ferrari, Fabrizio ;

Furgieri, Alessandro ;

Tumscitz, Carlo ;

Repetto, Alessandra ;

Colangelo, Salvatore ;

Meliga, Emanuele ;

Kubbajeh, Moh'd ;

Parrinello, Giovanni ;

Percoco, Gianfranco ;

Ferrari, Roberto .

CARDIOVASCULAR DRUGS AND THERAPY, 2008, 22 (04) :313-320

[25] Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study [J].